| Literature DB >> 32501272 |
Cheng-Sheng Yu1,2, Yu-Jiun Lin1,2, Chang-Hsien Lin1,2, Shiyng-Yu Lin1,2, Jenny L Wu1,2, Shy-Shin Chang1,2.
Abstract
BACKGROUND: In the era of information explosion, the use of the internet to assist with clinical practice and diagnosis has become a cutting-edge area of research. The application of medical informatics allows patients to be aware of their clinical conditions, which may contribute toward the prevention of several chronic diseases and disorders.Entities:
Keywords: machine learning; medical informatics; online healthcare assessment; preventive medicine
Year: 2020 PMID: 32501272 PMCID: PMC7305560 DOI: 10.2196/18585
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
The list of predicting variables in the electronic health care records.
| Disease and predicting variable | Unit | |
|
| ||
|
| Sex | Male/Female |
|
| Age | years |
|
| Body mass index | kg/m2 |
|
| Waist circumference | cm |
|
| Glutamic-oxaloacetic transaminase | IU/L |
|
| Glutamate pyruvate transaminase | IU/L |
|
| γ-Glutamyl transpeptidase | U/L |
|
| Total bilirubin | mg/dL |
|
| Alkaline phosphatase | IU/L |
|
| Blood urea nitrogen | mg/dL |
|
| Creatinine | mg/dL |
|
| Uric acid | mg/dL |
|
| Albumin | g/dL |
|
| Cholesterol | mg/dL |
|
| High-density lipoprotein | mg/dL |
|
| Low-density lipoprotein | mg/dL |
|
| Hemoglobin A1c | % |
|
| Glucose AC | mg/dL |
|
| Triglycerides | mg/dL |
|
| Systolic blood pressure | mm Hg |
|
| Diastolic blood pressure | mm Hg |
|
| Elastic modulus (E) score | kPa |
|
| Controlled attenuation parameter (CAP) score | dB/m |
|
| ||
|
| Sex | Male/Female |
|
| Age | years |
|
| Body mass index | kg/m2 |
|
| Waist circumference | cm |
|
| Glutamic-oxaloacetic transaminase | IU/L |
|
| Glutamate pyruvate transaminase | IU/L |
|
| γ-Glutamyl transpeptidase | U/L |
|
| Total bilirubin | mg/dL |
|
| Alkaline phosphatase | IU/L |
|
| Blood urea nitrogen | mg/dL |
|
| Creatinine | mg/dL |
|
| Uric acid | mg/dL |
|
| Albumin | g/dL |
|
| Cholesterol | mg/dL |
|
| High-density lipoprotein | mg/dL |
|
| Low-density lipoprotein | mg/dL |
|
| Hemoglobin A1c | % |
|
| Hypertension | Yes/No |
Figure 1The structure of web-based machine learning medical system. API: application programming interface; EMR: electronic medical record; ML: machine learning.
Figure 2Flowchart of data collection and preprocessing for MetS and CKD data sets including training and validation sets. SAS Enterprise Guide is a software that combines the analytic ability of SAS software with a user-friendly interface. It provides several functions of Structured Query Language (SQL), which includes a text mining technique. ACC: accuracy; AUC: area under the curve; BUN: blood urea nitrogen; CKD: chronic kidney disease; KNN: k-nearest neighbors algorithm; MetS: metabolic syndrome; UA: uric acid. * Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) [37], ** Iimori et al [39], *** De Nicola et al [38].
Figure 3Home page of the machine learning health care system.
Figure 4Interface of the input page for disease assessment.
Figure 5Outcome page for supervised learning models and the scoring system for disease diagnosis.
Figure 6Dynamic interactive heat map obtained using unsupervised clustering. Green: healthy patients; orange: CKD patients; blue: normal values; red: abnormal values. The new patients (yellow bar in red rectangle) are compared and clustered into the system’s patient database.
Characteristics of participants in the training and validation data set for metabolic syndrome.
| Characteristics | Training data set (n=904) | Validation data set (n=225) | |||
|
| |||||
|
| Female, n (%) | 411 (45.5) | 108 (48.0) | ||
|
| Male, n (%) | 493 (54.5) | 117 (52.0) | ||
| Age, years, median (IQR) | 44 (37-50.25) | 43 (38-50) | |||
| Body mass index, kg/m2, median (IQR) | 23.6 (21.3-25.9) | 22.9 (21.2-26) | |||
| Waist circumference, cm, median (IQR) | 81.75 (74.5-88) | 80.5 (74-87) | |||
| Albumin, g/dL, median (IQR) | 4.6 (4.4-4.8) | 4.6 (4.4-4.8) | |||
| Alkaline phosphatase, IU/L, median (IQR) | 58 (49-69) | 58 (48-69) | |||
| Glutamic-oxaloacetic transaminase, IU/L, median (IQR) | 20 (17-24.25) | 20 (17-25) | |||
| Glutamate pyruvate transaminase, IU/L, median (IQR) | 20 (14-31) | 19 (14-28) | |||
| Total bilirubin, mg/dL, median (IQR) | 0.6 (0.5-0.9) | 0.6 (0.4-0.8) | |||
| γ-Glutamyl transpeptidase, U/L, median (IQR) | 18 (12-27) | 17 (11.55-25) | |||
| Controlled attenuation parameter (CAP) score, dB/m, median (IQR) | 247 (211-284) | 241 (216-282) | |||
| Elastic modulus (E) score, kPa, median (IQR) | 4.2 (3.4-4.9) | 4 (3.3-4.8) | |||
| Blood urea nitrogen, mg/dL, median (IQR) | 12 (10-15) | 12 (10-14) | |||
| Creatinine, mg/dL, median (IQR) | 0.8 (0.6-0.9) | 0.8 (0.6-0.9) | |||
| Estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation, median (IQR) | 90.23 (80.49-104.77) | 91.28 (82.72-107.26) | |||
| Uric acid, mg/dL, median (IQR) | 5.5 (4.5-6.6) | 5.4 (4.3-6.6) | |||
| Systolic blood pressure, mm Hg, median (IQR) | 114 (105-125) | 114 (105-126) | |||
| Diastolic blood pressure, mm Hg, median (IQR) | 73 (67-80) | 72 (66-81) | |||
| Cholesterol, mg/dL, median (IQR) | 189 (165-209) | 185 (168-209) | |||
| Triglycerides, mg/dL, median (IQR) | 90 (65-135.2) | 86 (63-126) | |||
| High-density lipoprotein, mg/dL, median (IQR) | 55(45-67) | 54 (47-66) | |||
| Low-density lipoprotein, mg/dL, median (IQR) | 123 (102-145) | 123 (102-145) | |||
| Hemoglobin A1c, %, median (IQR) | 5.4 (5.2-5.6) | 5.4 (5.2-5.5) | |||
| Glucose AC, mg/dL, median (IQR) | 91 (86-96) | 90 (85-95) | |||
Characteristics of participants in the training and validation data sets for chronic kidney disease.
| Characteristics | Training data set (n=1830) | Validation data set, Taiwan (n=457) | Validation data set, United States (n=4434) | Validation data set, Italy (n=655) | Validation data set, Japan (n=996) |
| Sex, male, n (%) | 902 (49.29) | 209 (45.73) | 2165 (48.83) | 384 (58.63) | 696 (69.88) |
| Chronic kidney disease, n (%) | 164 (8.96) | 38 (8.32) | 410 (9.25) | 523 (79.85) | 919 (92.27) |
| Hypertension, n (%) | 522 (28.52) | 140 (30.63) | 1730 (39.02) | 599 (91.45) | 908 (91.16) |
| Age, years, median (IQR) | 46 (38-55) | 45 (37-55) | 53 (36-65) | 67 (56-74.5) | 70 (61-77) |
| Body mass index, kg/m2, median (IQR) | 23.8 (21.4-26.4) | 23.4 (21.3-26.2) | 28.6 (24.8-33.5) | 28.4 (25.8-31.6) | 23.25 (21-25.8) |
| Waist circumference, cm, median (IQR) | 82.5 (75.5-89.5) | 81 (75-89) | 99.5 (89-111.3) | —a | — |
| Glutamic-oxaloacetic transaminase, IU/L, median (IQR) | 21 (17-26) | 20 (17-25) | 19 (16-24) | — | — |
| Glutamate pyruvate transaminase, IU/L, median (IQR) | 20 (14-30) | 19 (13-28) | 18 (13-26) | — | — |
| γ-Glutamyl transpeptidase, U/L, median (IQR) | 19 (13-30) | 18 (12-33) | 21 (15-33) | — | — |
| Total bilirubin, mg/dL, median (IQR) | 0.6 (0.4-0.8) | 0.6 (0.4-0.8) | 0.4 (0.3-0.6) | — | — |
| Alkaline phosphatase, IU/L, median (IQR) | 62 (51-76) | 63 (50-78) | 75 (62-91) | — | — |
| Blood urea nitrogen, mg/dL, median (IQR) | 13 (11-16) | 13 (10-15) | 14 (11-18) | 28 (21.2-37.3) | — |
| Creatinine, mg/dL, median (IQR) | 0.8 (0.6-1.0) | 0.7 (0.6-0.9) | 0.85 (0.71-1.01) | 1.49 (1.2-1.9) | 1.8 (1.2-2.75) |
| Uric acid, mg/dL, median (IQR) | 5.5 (4.5-6.7) | 5.4 (4.5-6.5) | 5.3 (4.4-6.4) | 6.3 (5.2-7.6) | — |
| Albumin, g/dL, median (IQR) | 4.6 (4.4-4.8) | 4.6 (4.4-4.8) | 4.1 (3.9-4.3) | 4 (3.7-4.3) | 4 (3.5-4.3) |
| Cholesterol, mg/dL, median (IQR) | 186 (164-210) | 185 (160-209) | 185 (160-214) | 189 (162.5-218) | — |
| High-density lipoprotein, mg/dL, median (IQR) | 52 (44-64) | 53 (43-64) | 51 (42-61) | — | — |
| Low-density lipoprotein, mg/dL, median (IQR) | 121 (100-145) | 120 (100-142) | — | — | — |
| Hemoglobin A1c, %, median (IQR) | 5.4 (5.2-5.6) | 5.4 (5.2-5.7) | 5.6 (5.3-6) | — | — |
aNot available.
The performance of supervised learning models on predicting metabolic syndrome and chronic kidney disease.
| Model and disease | Accuracy | Area under the curve (AUC) | F1 score | |
|
| ||||
|
| Metabolic syndrome (Taiwan) | 0.874 | 0.887 | 0.448 |
|
| Chronic kidney disease (Taiwan) | 0.945 | 0.928 | 0.965 |
|
| ||||
|
| Metabolic syndrome (Taiwan) | 0.909 | 0.904 | 0.610 |
|
| Chronic kidney disease (Taiwan) | 0.947 | 0.982 | 0.989 |
|
| Chronic kidney disease (United States) | 0.951 | 0.929 | 0.679 |
|
| Chronic kidney disease (Italy) | 0.881 | 0.977 | 0.920 |
|
| Chronic kidney disease (Japan) | 0.743 | 0.923 | 0.838 |